GlassScriptPhysician profile
Paul Friedman
NPI 1386646040
$58,274.32
in general payments reported to CMS, 2019-2025
30 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $13K · 2021: $20K · 2022: $5,945 · 2023: $2,094 · 2024: $1,748 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,543 · Education: $86.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,543.05 |
| Education | $86.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49,145.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,139.24 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Philips North America LLC | $1,171.74 | 2019-2025 | Vest Therapy Und, (8874) Incourage |
| Regeneron Healthcare Solutions, INC. | $968.50 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $934.67 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $826.28 | 2019-2025 | |
| Amgen INC. | $416.75 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $363.83 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $210.98 | 2021-2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $172.50 | 2019-2025 | Uptravi |
| Electromed, INC. | $157.64 | 2019-2023 | Smartvest |
| Genentech USA, INC. | $109.66 | 2019-2023 | Xolair |
| Covis Pharma Gmbh | $106.86 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $65.97 | 2023-2024 | |
| Insmed, INC. | $61.57 | 2019-2025 | Arikayce |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $60.07 | 2019-2020 | |
| Viatris Specialty LLC | $58.50 | 2025 | Yupelri |
| Baxter Healthcare | $52.47 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $50.64 | 2020-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $41.08 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $23.51 | 2019-2021 | |
| Harmony Biosciences LLC | $22.34 | 2022-2024 | |
| Shionogi INC | $17.68 | 2024 | Fetroja |
| Verona Pharma, INC. | $17.28 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $14.20 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.10 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.08 | 2021 | |
| Sanofi Pasteur INC. | $13.06 | 2019 | |
| Optinose US, INC. | $12.40 | 2021 | |
| Pfizer INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.